TY - JOUR
T1 - 基于斑马鱼模型探讨血必净注射液与3种抗生素并用对肝损伤的影响
AU - Chen, Zhao
AU - Zheng, Rui
AU - Zhang, Xiaoyu
AU - Qiu, Ruijin
AU - Pan, Haie
AU - Sun, Yang
AU - Zhao, Chen
AU - Tian, Guihua
AU - Shang, Hongcai
N1 - Publisher Copyright:
© 2021 Drug Evaluation Research. All rights reserved.
PY - 2021/7
Y1 - 2021/7
N2 - Objective: To evaluate the effects of Xuebijing Injection and three kinds of antibiotics on liver protection and liver injury by zebrafish model. Methods: Zebrafish with liver fluorescent labeling were used as animal models. The control group, single antibiotic group (amoxicillin clavulanate potassium dispersible tablet 1 000 μg/mL, levofloxacin tablet 800 μg/mL, amoxicillin capsule 400 μg/mL), Xuebijing Injection (2.5, 5.0, 10.0 μg/mL) + antibiotic group were set for continuous administration for 72 h. Change the exposure solution every 24 hours, After administration, the liver area, and liver fluorescence intensity were counted. Samples collection, paraffin embedding, paraffin section, HE staining, and histopathological examination were performed. Results: The experimental results showed that there were no death and no aggravation of toxicity within the safe dose range of amoxicillinclavulanate potassium, combing with Xuebijing (2.5, 5, 10 μL/mL). With the increasing of Xuebijing concentration, the liver area and fluorescence intensity increased gradually. Within the safe dose range of levofloxacin, no increase in toxicity was found combing with Xuebijing (2.5, 5, 10 μL/mL). Within the safe concentration range of amoxicillin, combined application of 10 μL/mL Xuebijing Injection could cause death of all zebrafish. The combined application of 5 μL/mL Xuebijing Injection could cause the death of some zebrafish, and the liver toxicity of the remaining zebrafish was aggravated. Compared with the group of amoxicillin capsule alone, the liver area and liver fluorescence intensity were significantly decreased (P < 0.05). Conclusion: The combined use of Xuebijing Injection and amoxicillin-clavulanate potassium will not cause damage to the liver of zebrafish. The combined use of amoxicillin and Xuebijing Injection will increase the risk of liver injury in zebrafish, and high doses may lead to death. When using Xuebijing Injection clinically, the prescribed dose of amoxicillin should be controlled and the changes in liver function should be observed. The combined use of Xuebijing Injection and levofloxacin has not found any damage to the liver of zebrafish.
AB - Objective: To evaluate the effects of Xuebijing Injection and three kinds of antibiotics on liver protection and liver injury by zebrafish model. Methods: Zebrafish with liver fluorescent labeling were used as animal models. The control group, single antibiotic group (amoxicillin clavulanate potassium dispersible tablet 1 000 μg/mL, levofloxacin tablet 800 μg/mL, amoxicillin capsule 400 μg/mL), Xuebijing Injection (2.5, 5.0, 10.0 μg/mL) + antibiotic group were set for continuous administration for 72 h. Change the exposure solution every 24 hours, After administration, the liver area, and liver fluorescence intensity were counted. Samples collection, paraffin embedding, paraffin section, HE staining, and histopathological examination were performed. Results: The experimental results showed that there were no death and no aggravation of toxicity within the safe dose range of amoxicillinclavulanate potassium, combing with Xuebijing (2.5, 5, 10 μL/mL). With the increasing of Xuebijing concentration, the liver area and fluorescence intensity increased gradually. Within the safe dose range of levofloxacin, no increase in toxicity was found combing with Xuebijing (2.5, 5, 10 μL/mL). Within the safe concentration range of amoxicillin, combined application of 10 μL/mL Xuebijing Injection could cause death of all zebrafish. The combined application of 5 μL/mL Xuebijing Injection could cause the death of some zebrafish, and the liver toxicity of the remaining zebrafish was aggravated. Compared with the group of amoxicillin capsule alone, the liver area and liver fluorescence intensity were significantly decreased (P < 0.05). Conclusion: The combined use of Xuebijing Injection and amoxicillin-clavulanate potassium will not cause damage to the liver of zebrafish. The combined use of amoxicillin and Xuebijing Injection will increase the risk of liver injury in zebrafish, and high doses may lead to death. When using Xuebijing Injection clinically, the prescribed dose of amoxicillin should be controlled and the changes in liver function should be observed. The combined use of Xuebijing Injection and levofloxacin has not found any damage to the liver of zebrafish.
KW - Xuebijing Injection
KW - amoxicillin
KW - amoxicillin-clavulanate potassium
KW - antibiotic
KW - combination of traditional Chinese medicine and Western medicine
KW - drug interactions
KW - levofloxacin
KW - zebrafish model
UR - http://www.scopus.com/inward/record.url?scp=85132550803&partnerID=8YFLogxK
U2 - 10.7501/j.issn.1674-6376.2021.07.004
DO - 10.7501/j.issn.1674-6376.2021.07.004
M3 - 文章
AN - SCOPUS:85132550803
SN - 1674-6376
VL - 44
SP - 1385
EP - 1391
JO - Drug Evaluation Research
JF - Drug Evaluation Research
IS - 7
ER -